the zero tolerance criterion, and this is for the small test, same thing with the big PTI test.
Now, we can take the most extreme non-normal case which is the asymmetric short-tailed beta distribution with alpha equal to 2, beta equal to 100, off target at the worst position. We see, as I've told you, that the acceptance rate exceeds the ideal 5 percent, but we can also see that the addition of this problematic zero tolerance criterion doesn't really materially improve this consumer protection. So the conclusion still is that zero tolerance is not helpful in product quality assessment.
Now, I've given you the overview with focus on most of the issues, such as revising the coefficients to make true the 5 percent error rate. I've discussed the quality standard, the perceived gap between the FDA and the PTI OC curve, issues about non-normality and zero tolerance criterion, and I hope that we can all agree that the PTI test is conceptually acceptable as a replacement, parametric without the zero tolerance criterion and with coverage as the quality definition.
A desirable characteristic of the test is that it allows product-by-product justification of the sample